Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): Review of development and future perspectives

Surgery Today

Volumn 42, Issue 1, 2012, Pages 8-28

  Maehara, Yoshihiko ^a   Tsujitani, Shunichi ^a   Saeki, Hiroshi ^a   Oki, Eiji ^a   Yoshinaga, Keiji ^a   Emi, Yasunori ^a   Morita, Masaru ^a   Kohnoe, Shunji ^a   Kakeji, Yoshihiro ^a   Yano, Tokujiro ^a   Baba, Hideo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Biological mechanism; Biomarker; Colorectal cancer; Gastric cancer; PSK

Indexed keywords

CARBOQUONE; CARMOFUR; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; FOLINIC ACID; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; IRINOTECAN; KRESTIN; LYMPHOKINE; LYMPHOTACTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 6; MITOMYCIN C; PICIBANIL; PLACEBO; PROSTAGLANDIN E2; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; SURVIVIN; TEGAFUR; TRANSFORMING GROWTH FACTOR BETA; UFT; UNINDEXED DRUG; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADVERSE OUTCOME; ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVATION; CELL ACTIVITY; CELL MATURATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MONOCYTE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STOMACH CANCER; SURVIVAL RATE; TARGET CELL; TH1 TH2 BALANCE; TREATMENT DURATION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMOTHERAPY, ADJUVANT; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEOGLYCANS;

EID: 84857795063     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-0075-7     Document Type: Review

References (117)

1. P van der Bruggen C Traversari P Chomez C Lurquin E De Plaen B Van den Eynde, et al. 1991 A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1643 1647 1840703 10.1126/science.1840703 (Pubitemid 21917508)
2. SA Rosenberg 2001 Progress in human tumour immunology and immunotherapy Nature 411 380 384 11357146 10.1038/35077246 1:CAS:528:DC%2BD3MXktVSjs70%3D (Pubitemid 32467048)
3. J Banchereau RM Steinman 1998 Dendritic cells and the control of immunity Nature 392 245 252 9521319 10.1038/32588 1:CAS:528:DyaK1cXitFWrsr8%3D (Pubitemid 28155090)
4. S Akira K Takeda T Kaisho 2001 Toll-like receptors: critical proteins linking innate and acquired immunity Nat Immunol 2 675 680 11477402 10.1038/90609 1:CAS:528:DC%2BD3MXlslGjtLs%3D (Pubitemid 32747155)
5. K Yoshimura K Olino BH Edil RD Schulick M Oka 2010 Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer) Surg Today 40 404 410 20425541 10.1007/s00595-009-4120-8 1:CAS:528:DC%2BC3cXltlyrur0%3D
6. DJ Sargent CH Köhne HK Sanoff BM Bot MT Seymour A de Gramont, et al. 2009 Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer J Clin Oncol 27 1948 1955 19255311 10.1200/JCO.2008.20.2879
7. SS Donaldson RA Lenon 1979 Alterations of nutritional status: impact of chemotherapy and radiation therapy Cancer 43 2036 2052 109184 10.1002/1097-0142(197905)43:5+<2036::AID-CNCR2820430712>3.0.CO;2-7 1:CAS:528:DyaE1MXkvValu7c%3D (Pubitemid 9200539)
8. J Sakamoto S Teramukai A Koike S Saji Y Ohashi H Nakazato 1996 Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma: findings from three independent clinical trials Cancer 77 2206 2212 8635085 10.1002/(SICI)1097-0142(19960601)77:11<2206::AID-CNCR4>3.0.CO;2-N 1:STN:280:DyaK283isVyrsQ%3D%3D (Pubitemid 26162410)
9. L Apetoh F Ghiringhelli A Tesniere M Obeid C Ortiz A Criollo, et al. 2007 Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 1050 1059 17704786 10.1038/nm1622 1:CAS:528:DC%2BD2sXhtVSgtr3E (Pubitemid 47517504)
10. S Tsukagoshi Y Hashimoto G Fujii H Kobayashi K Nomoto K Orita 1984 Krestin (PSK) Cancer Treat Rev 11 31 55 10.1016/0305-7372(84)90005-7
11. Fujii M. Krestin (PSK). Biotherapy. 1996;10:315-7 (in Japanese with English abstract).
12. K Matsunaga I Morita H Iijima H Endo Y Oguchi M Yoshimura, et al. 1990 Competitive action of biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts J Clin Lab Immunol 31 127 136 1966997 1:STN:280:DyaK38zgvFersQ%3D%3D
13. T Hattori T Nakajima H Nakazato T Tanabe K Kikuchi O Abe, et al. 1990 Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy Jpn J Surg 20 127 136 2111414 10.1007/BF02470759 1:STN:280:DyaK3c3lvVansQ%3D%3D (Pubitemid 20334501)
14. + T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice Int J Cancer 70 362 372 9033641 10.1002/(SICI)1097-0215(19970127)70: 3<362::AID-IJC19>3.0.CO;2-H 1:CAS:528:DyaK2sXhs1Omsrs%3D (Pubitemid 27099608)
15. K Matsunaga A Hosokawa M Oohara N Sugita M Harada K Nomoto 1998 Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-β Immunopharmacology 40 219 230 9858065 10.1016/S0162-3109(98)00045- 9 1:CAS:528:DyaK1cXntVyhu7s%3D (Pubitemid 28522180)
16. Inokuchi K, Kumashiro R. Chemotherapy for gastric cancer. Surg Therapy. 1980;42:40-6 (in Japanese).
17. Yamanaka M, Takahata K, Oka H, Yoshino F, Sugita N, Yoshikumi C. Studies on the mechanisms of antitumor activities of PSK (Krestin): effects on prostaglandin metabolism of tumor cells. In: Ishigami J, editor. Recent advances in chemotherapy. Proceedings of the 14th ICC. Tokyo: University of Tokyo Press; 1985. p. 896-7.
18. Y Kobayashi K Kariya K Saigenji K Nakamura 1994 Oxidative stress relief for cancer-bearing hosts by the protein-bound polysaccharide of Coriolus versicolor Quel with SOD mimicking activity Cancer Biother 9 55 62 7812357 10.1089/cbr.1994.9.55 1:CAS:528:DyaK2cXkt1Knsrw%3D
19. Y Yamaguchi K Minami A Ohshita Y Kawabuchi K Noma T Toge 2004 Enhancing effect of PS-K on IL-2-induced lymphocyte activation: possible involvement of antagonistic action against TGF-beta Anticancer Res 24 639 648 15161006 1:CAS:528:DC%2BD2cXkvVensr4%3D
20. Shibata M, Abe H, Kanou H, Azuhata T, Nezu T, Ohara M, et al. In vitro and in vivo immune-modulating effects of polysaccharide-K (PSK) in patients with colorectal cancer. Proc AACR. 2002;43:448.
21. M Shibata T Nezu H Kanou Y Nagata T Kimura M Takekawa, et al. 2002 Immunomodulatory effects of low dose cis-diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer Cancer Invest 20 166 173 11901535 10.1081/CNV-120001142 1:CAS:528:DC%2BD38XivFCqsrk%3D (Pubitemid 34205482)
22. + T cells and efficacy of polysaccharide K (PSK) in gastric cancer J Clin Oncol 26 148s
23. M Okuzawa H Shinohara T Kobayashi M Iwamoto M Toyoda N Tanigawa 2002 PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro Int J Oncol 20 1189 1195 12011998 1:CAS:528:DC%2BD38XksF2ns7c%3D
24. Sugiyama Y, Saji S, Kunieda K, Yamada M, Nagata M, Ri S, et al. Effect of PSK on either immunocytes or tumor cells. Biotherapy. 1996;10:18-25 (in Japanese with English abstract). (Pubitemid 26068294)
25. M Ooshiro Y Sugishita H Tanaka K Koide M Nagashima R Katoh 2004 Regulation of perioperative immunological changes following laparotomy: effects of biological response modifier (BRM) on surgical stress Immunol Lett 93 33 38 15134896 10.1016/j.imlet.2004.01.008 1:CAS:528:DC%2BD2cXjvVeqsLo%3D (Pubitemid 38591517)
26. Tsukagoshi S. Fundamental approaches to cancer immunotherapy using a protein-bound polysaccharide, PS-K, with special reference to its clinical application. In: Mizuno D, Chihara G, Fukuoka F, Yamamoto T, Yamamura Y, editors. Host defense against cancer and its potentiation. Tokyo: University of Tokyo Press; 1975. p. 365-77.
27. K Kono Y Kawaguchi Y Mizukami K Mimura H Sugai H Akaike, et al. 2008 Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drugs S-1 in patients with gastric cancer Oncology 74 143 149 18708731 10.1159/000151361 1:CAS:528:DC%2BD1cXhtVOnur7J
28. Y Kariya N Okamoto T Fujimoto N Inoue T Kihara K Sugie, et al. 1991 Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK Jpn J Cancer Res 82 1044 1050 1938599 10.1111/j.1349-7006.1991.tb01941.x 1:STN:280:DyaK38%2FktFajsQ%3D%3D
29. Y Nio T Shiraishi M Tsubono H Morimoto CC Tseng C Imai, et al. 1991 In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer Cancer Immunol Immunother 32 335 341 1901030 10.1007/BF01741328 1:STN:280:DyaK3M7ns1Crsg%3D%3D
30. F Vánky P Wang E Klein 1992 The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumor cells Cancer Immunol Immunother 353 193 198 10.1007/BF01756187
31. T Ebina H Kohya 1988 Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation Jpn J Cancer Res 79 957 964 3141330 10.1111/j.1349-7006.1988. tb00061.x
32. S Tsuru K Nomoto 1983 Effects of PSK on specific tumor immunity to syngeneic tumor cells J Clin Lab Immunol 10 215 219 6408260 1:CAS:528: DyaL3sXktVShtbs%3D (Pubitemid 13124002)
33. I Algarra A Collado F Garrido 1997 Protein bound polysaccharide PSK abrogates more efficiently experimental metastasis derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones J Exp Clin Cancer Res 16 373 380 9505208 1:CAS:528:DyaK1cXhtVClsrc%3D (Pubitemid 28083536)
34. Ueda Y, Naito K, Kobayashi M, Omori K, Shimode Y, Matsuda A, et al. In vitro induction of LAK cells with PSK. Biotherapy. 1991;5:861-3 (in Japanese with English abstract).
35. Baba N, Yamaguchi Y, Sato Y, Takayama T, Yanagawa E, Toge T. The enhancement of tumoricidal activities of macrophages by protein-bound polysaccharide in tumor bearing mice. Biotherapy. 1990;4:123-8 (in Japanese with English abstract).
36. H Kato R Kin Y Yamamura M Tanigawa H Sano S Sugino, et al. 1987 Tumor inhibitory effect of polymorphonuclear leukocytes (PMN) induced by PSK in the peritoneal cavity of tumor-bearing mice J Kyoto Pref Univ Med 96 927 938 1:CAS:528:DyaL1cXmvVCrtg%3D%3D
37. K Hirose C Zachariae J Oppenheim M Kouji 1990 Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells Lymphokine Res 94 475 483 (Pubitemid 20384838)
38. K Asai H Kato S Kimura S Mukai Y Kawahito H Sano, et al. 1996 Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line Cancer Immunol Immunother 42 275 279 8706048 10.1007/s002620050282 1:CAS:528:DyaK28Xlslymu7k%3D (Pubitemid 26281091)
39. A García-Lora S Pedrinaci F Garrido 2001 Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line Cancer Immunol Immunother 50 191 198 11459171 10.1007/s002620100189 (Pubitemid 32663906)
40. A García-Lora M Martinez S Pedrinaci F Garrido 2003 Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line Cancer Immunol Immunother 52 59 64 12536241 (Pubitemid 36181530)
41. + T cells by modulating T cell receptor signaling Cancer Immunol Immunother 57 1647 1655 18343922 10.1007/s00262-008-0498-1 1:CAS:528: DC%2BD1cXhtVejsbbP
42. M Kanazawa Y Mori K Yoshihara M Iwadate S Suzuki Y Endoh, et al. 2004 Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocytes Immunol Lett 91 229 238 15019294 10.1016/j.imlet.2003.12.007 1:CAS:528:DC%2BD2cXhs12nu70%3D (Pubitemid 38296383)
43. T Ogihara H Iinuma K Okinaga 2004 Usefulness of immunomodulators for maturation of dendritic cells Int J Oncol 25 453 459 15254744 1:CAS:528:DC%2BD2cXmvF2ru7g%3D
44. + T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells Cell Immunol 150 114 123 8102084 10.1006/cimm.1993.1183 1:STN:280:DyaK3szksFShuw%3D%3D (Pubitemid 23250867)
45. Sugiyama Y, Osada S, Yamaguchi K, Nagao N, Takahashi T, Sakashita F. Evidence-based biotherapy by use of PSK. Biotherapy. 2006;20:396-402 (in Japanese with English abstract). (Pubitemid 44379520)
46. Yoshino S, Hazama S, Shimizu R, Fukuda S, Kudoh A, Mizuta E, et al. Usefulness in predicting parameters for the selection of responders who received immunochemotherapy with PSK in patients with colorectal cancer. Jpn J Cancer Chemother. 2005;32:1568-70 (in Japanese with English abstract).
47. T Kanoh K Saito K Matsunaga Y Oguchi N Taniguchi H Endoh, et al. 1994 Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody the protein-bound polysaccharide PSK in mice bearing a human cancer cell line In Vivo 8 241 245 7919129 1:CAS:528:DyaK2cXlvFGhsr8%3D
48. K Nomoto C Yoshikumi K Matsunaga T Fujii K Takeya 1975 Restoration of antibody-forming capacities by PS-K in tumor bearing mice Gann 66 365 374 1183773 1:STN:280:DyaE28%2FksVCntw%3D%3D
49. S Maruyama T Akasaka K Yamada H Tachibana 2009 Protein-bound polysaccharide-K (PSK) directly enhanced IgM production in the human B cell line BALL-1 Biomed Pharmacother 63 409 412 18848763 10.1016/j.biopha.2008.08.006 1:CAS:528:DC%2BD1MXosVGlsbk%3D
50. A Liu G Klein K Bandobashi E Klein N Nagy 2002 SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK Immunol Lett 80 81 88 10.1016/S0165- 2478(01)00312-1 (Pubitemid 34025081)
51. A Liu JL Arbiser A Holmgren G Klein E Klein 2005 PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12 Blood 105 1606 1613 15507528 10.1182/blood-2004-06-2406 1:CAS:528:DC%2BD2MXhsVChtbc%3D (Pubitemid 40223681)
52. 4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures Blood 111 2693 2703 18094330 10.1182/blood-2007-08-102319 1:CAS:528:DC%2BD1cXivFaktb4%3D
53. 4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures Immunol Lett 116 174 177 18241933 10.1016/j.imlet.2007.12.006 1:CAS:528:DC%2BD1cXjtVWrtrs%3D
54. + T cells to improve survival of advanced gastric cancer patients Int J Clin Oncol 15 145 152 20229169 10.1007/s10147-010-0033-1 1:CAS:528:DC%2BC3cXksFGms7w%3D
55. Y Asai K Takaori T Yamamoto T Ogawa 2005 Protein-bound polysaccharide isolated from basidiomycetes inhibits endotoxin-induced activation by blocking lipopolysaccharide-binding protein and CD14 functions FEMS Immunol Med Microbiol 43 91 98 15607641 10.1016/j.femsim.2004.07.008 1:CAS:528:DC%2BD2cXhtVyqs7zJ (Pubitemid 40029432)
56. C Miki K Tanaka Y Inoue T Araki M Ohi Y Mohri, et al. 2008 Perioperative host-tumor inflammatory interactions: a potential trigger for disease recurrence following a curative resection for colorectal cancer Surg Today 38 579 584 18612780 10.1007/s00595-007-3674-6 (Pubitemid 351977650)
57. N Tsutsumi S Kohnoe H Sonoda A Guntani T Rikimaru K Taguchi, et al. 2011 Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo Oncol Lett 2 791 796 1:CAS:528: DC%2BC3MXhtFSrsLvO
58. Yanagawa T, Oguro M, Takagi T, Takenaga K. Direct antitumor activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test. Jpn J Cancer Chemother. 1984;11:2155-62 (in Japanese with English abstract). (Pubitemid 14019376)
59. E Yefenof I Gafanovitch E Oron M Bar E Klein 1995 Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K Cancer Immunol Immunother 41 389 396 8635197 10.1007/BF01526559 1:CAS:528:DyaK28XitVKit70%3D (Pubitemid 26045108)
60. Araya S, Nio Y, Hayashi H, Masai Y, Tsubono M, Ishigami S, et al. Various plant-derived polysaccharides augment the expression of HLA on Colo 205 human colonic cancer line. J Jpn Soc Cancer Ther. 1994;29:1965-73 (in Japanese with English abstract).
61. ST Hattori N Komatsu S Shichijo K Itoh 2004 Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa Biomed Pharmacother 58 226 230 15183847 10.1016/j.biopha.2004.02.004 1:CAS:528:DC%2BD2cXks1Wksr0%3D (Pubitemid 38746748)
62. E Jiménez-Medina E Berruguilla I Romero I Algarra A Collado F Garrido, et al. 2008 The immunomodulator PSK induces in vitro cytotoxic activity in tumor cell lines via arrest of cell cycle, induction of apoptosis BMC Cancer 8 78 18366723 10.1186/1471-2407-8-78
63. H Kobayashi K Matsunaga Y Oguchi 1995 Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from Basidiomycetes: an overview Cancer Epidemiol Biomarkers Prev 4 275 281 7606203 1:CAS:528: DyaK2MXlslCqs74%3D
64. H Zhang T Morisaki H Matsunaga N Sato A Uchiyam K Hashizume, et al. 2000 Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-β1 and MMPs Clin Exp Metastasis 18 343 352 11448066 1:CAS:528:DC%2BD3MXlsVOrt7w%3D (Pubitemid 32579404)
65. JP Thiery JP Sleeman 2006 Complex networks orchestrate epithelial-mesenchymal transitions Nat Rev Mol Cell Biol 7 131 142 16493418 10.1038/nrm1835 1:CAS:528:DC%2BD28XhtlWltLg%3D (Pubitemid 43278296)
66. Hayashida T, Konagi A, Hasegawa H, Ishii Y, Endo T, Okabayashi K, et al. Inhibitory ability of a protein-bound polysaccharide, PSK, on transforming growth factor beta pathway and EMT. In: Proceedings of the JCA. 2009; p. 47.
67. Kumar S, Saitoh K, Kumar P. Angiogenesis: key principles-science- technology-medicine. In: Steiner R, Weisz PB, Langer R, editors. Antiangiogenesis strategies in cancer therapy with special reference to Krestin. Basel: Birkhauser Verlag; 1992. p. 463-70.
68. T Wada Y Wakamatsu K Bannai M Kato Y Oguchi K Matsunaga, et al. 2002 Suppression mechanism of angiogenesis by PSK Ann Cancer Res Ther 10 93 106 1:CAS:528:DC%2BD3sXmsFGgt74%3D (Pubitemid 39334881)
69. H Konno M Yamamoto M Ohta 2010 Recent concepts of antiangiogenic therapy Surg Today 40 494 500 20496129 10.1007/s00595-009-4150-2
70. R Yoshikawa H Yanagi T Hashimoto-Tamaoki T Morinaga Y Nakano M Noda, et al. 2004 Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells Oncology Rep 12 1287 1293 1:CAS:528:DC%2BD2MXitFOksw%3D%3D
71. H Zhang T Morisaki C Nakahara H Matsunaga N Sato F Nagumo, et al. 2003 PSK-mediated NF-κB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1 Oncogene 22 2088 2096 12687011 10.1038/sj.onc.1206310 1:CAS:528:DC%2BD3sXislyiur8%3D (Pubitemid 36539559)
72. J Kinoshita S Fushida S Harada I Makino K Nakamura K Oyama, et al. 2010 PSK enhances the efficacy of docetaxel in human gastric cancer cells through inhibition of nuclear factor-kappaB activation and survivin expression Int J Oncol 36 593 600 20126979 10.3892/ijo-00000534 1:CAS:528:DC%2BC3cXjs1Ggtb8%3D
73. Sakurai Y, Azuma I, Ishihara K, Ogura T, Saito T, Simoyama M, et al. Method for evaluation of efficacy of immunopotentiating agent on malignant tumor. Pharm Regul Sci. 1980;11:764-8 (in Japanese).
74. Nakao I, Yokoyama T, Urushizaki I, Wakui A, Furue H, Koyama Y, et al. Clinical outcome of PSK for advanced gastric cancer-results of randomized control trial. Oncologia. 1985;14:163-9 (in Japanese).
75. Y Maehara H Baba K Sugimachi 2001 Adjuvant chemotherapy for gastric cancer: a comprehensive review Gastric Cancer 4 175 184 11846060 10.1007/s10120-001-8008-6 1:CAS:528:DC%2BD38XislCksbs%3D (Pubitemid 34194976)
76. Kondo M, Torisu M, Evaluation of an anticancer activity of a protein-bound polysaccharide PS-K (Krestin). In: Torisu M, Yoshida T, editors. Basic mechanisms and clinical treatment of tumor metastasis. Orlando: Academic Press; 1985. p. 623-36.
77. Y Maehara S Moriguchi Y Sakaguchi Y Emi S Kohnoe S Tsujitani, et al. 1990 Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection J Surg Oncol 45 169 172 2122131 10.1002/jso.2930450307 1:STN:280:DyaK3M%2FktVyksA%3D%3D (Pubitemid 20382891)
78. Nakajima T, Inokuchi K, Hattori T, Inoue K, Taguchi T, Kondou T, et.al. Multi-institutional cooperative study of adjuvant immunochemotherapy for gastric cancer-five-year survival rate. Jpn J Cancer Chemother. 1989;16:799-806 (in Japanese with English abstract). (Pubitemid 19119751)
79. M Niimoto T Hattori R Tamada K Sugimachi K Inokuchi N Ogawa 1988 Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years Jpn J Surg 18 681 686 3150019 10.1007/BF02471530 1:STN:280:DyaL1M3js1yjuw%3D%3D (Pubitemid 19057878)
80. Kondo T, Ichihashi H, Nakazato H, Ogawa N. Results of adjuvant immunochemotherapy on 8-year survival using KRESTIN® and Futraful® for gastric cancer patients who underwent radical gastrectomy-a randomized controlled trial by cooperative study group. Biotherapy. 1989;3:655-64 (in Japanese with English abstract).
81. Sakamoto J, Nakazato H, Koike A, Saji S. Pitfalls in the clinical evaluation of surgical adjuvant immunochemotherapy for the multidisciplinary treatment of gastrointestinal cancers. Biotherapy. 1993;7:1759-64 (in Japanese with English abstract).
82. T Kondo J Sakamoto H Nakazato 1991 Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection Biotherapy 3 287 295 1786194 10.1007/BF02221321 1:STN:280:DyaK387ltlKiuw%3D%3D
83. H Nakazato A Koike S Saji N Ogawa J Sakamoto 1994 Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer Lancet 343 1122 1126 7910230 10.1016/S0140-6736(94)90233-X 1:STN:280:DyaK2c3jvFShtQ%3D%3D (Pubitemid 24142032)
84. Ogawa M, Kako H, Kitano K, Matsukane H, Nagao K, Misumi A, et al. Cooperative study of adjuvant immunochemotherapy using HUFU (Mifurol®) for gastric cancer patients who underwent curative resection. Rinsyo To Kenkyu. 1994;71:201-6 (in Japanese).
85. K Oba S Teramukai M Kobayashi T Matsui Y Kodera J Sakamoto 2007 Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer Cancer Immunol Immunother 56 905 911 17106715 10.1007/s00262-006-0248-1 1:CAS:528:DC%2BD2sXjsFyhtbg%3D (Pubitemid 46729147)
86. K Sugimachi Y Maehara M Ogawa T Kakegawa M Tomita 1997 Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer Cancer Chemother Pharmacol 40 233 238 9219507 10.1007/s002800050652 1:CAS:528:DyaK2sXjvF2kuro%3D (Pubitemid 27257737)
87. M Fujii M Kochi T Takayama 2010 Recent advances in chemotherapy for advanced gastric cancer in Japan Surg Today 40 295 300 20339982 10.1007/s00595-009-4148-9 1:CAS:528:DC%2BC3cXjvVGhsL4%3D
88. M Torisu Y Hayashi T Ishimitsu T Fujimura K Iwasaki M Katano, et al. 1990 Significant prolongation of disease-free period gained by oral polysaccharide K(PSK) administration after curative surgical operation of colorectal cancer Cancer Immunol Immunother 31 261 268 2198088 10.1007/BF01740932 1:STN:280:DyaK3czivFKisw%3D%3D (Pubitemid 20230287)
89. Takashima S, Kinami Y, Miyazaki I. Clinical effect of postoperative adjuvant immunochemotherapy with FT-207 suppository and PSK for colo-rectal cancer patients. Jpn J Cancer Chemother. 1988;15:2229-36 (in Japanese with English abstract).
90. Mitomi T, Tsuchiya S, Iijima N, Aso K, Nishiyama K, Amano T, et al. Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer-5 years follow-up after surgery (a final report). J Jpn Soc Cancer Ther. 1993;28:71-83 (in Japanese with English abstract). (Pubitemid 23064731)
91. K Ito H Nakazato A Koike H Takagi S Saji S Baba, et al. 2004 Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up Int J Colorectal Dis 19 157 164 13680286 10.1007/s00384-003-0532-x (Pubitemid 38239838)
92. S Ohwada T Ikeya T Yokomori T Kusaba T Roppongi T Takahashi, et al. 2004 Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study Br J Cancer 90 1003 1010 14997197 10.1038/sj.bjc.6601619 1:CAS:528:DC%2BD2cXhslWrsL4%3D (Pubitemid 38495819)
93. J Sakamoto S Morita K Oba T Matsui M Kobayashi H Nakazato, et al. 2006 Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials Cancer Immunol Immunother 55 404 411 16133112 10.1007/s00262-005-0054-1 1:CAS:528:DC%2BD28XjtVyisw%3D%3D (Pubitemid 43076892)
94. Konno K, Motomiya M, Oizumi K, Sato M, Yamamoto F, Tamiya K, et al. Effects of protein-bound polysaccharide preparation (PSK) in small cell carcinoma of the lung. JJLC. 1988;28:19-28 (in Japanese with English abstract). (Pubitemid 18072736)
95. Ikeda T, Sakai T, SuitoT, Kosaki G. Evaluation of postoperative immunochemotherapy for lung cancer patients. Jpn J Cancer Chemother. 1986;13:1044-9 (in Japanese with English abstract). (Pubitemid 17217774)
96. K Hayakawa N Mitsuhashi Y Saito Y Nakayama M Furuta S Nakamoto, et al. 1997 Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients Cancer Detect Prev 21 71 77 9043766 1:CAS:528:DyaK2sXhvVSmtrg%3D (Pubitemid 27307074)
97. P Go CH Chung 1989 Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx J Int Med Res 17 141 149 2656331 1:STN:280: DyaL1M3lt1Cgug%3D%3D (Pubitemid 19100697)
98. Matsumoto K, Nakagami Y, Kishimoto T. The prevention of recurrence of superficical bladder tumours with immunochemotherapy. In: deKernion JB, editor. International society of urology reports. Immunotherapy of urological tumours. Edinburgh: Churchill Livingstone; 1990. p. 149-55.
99. K Ogoshi H Satou K Isono T Mitomi M Endoh M Sugita 1995 Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy Am J Clin Oncol 18 216 222 7747709 10.1097/00000421-199506000- 00007 1:STN:280:DyaK2M3ms1GmsA%3D%3D
100. Y Iino T Yokoe M Maemura J Horiguchi H Takei S Ohwada, et al. 1995 Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer Anticancer Res 15 2907 2911 8669887 1:CAS:528:DyaK28Xitl2itrk%3D (Pubitemid 26095121)
101. Pharmaceutical Affairs Bureau, Ministry of Health and Welfare (Japan). Ethical drug side effect information no. 48. 1982; p. 220-3 (in Japanese).
102. Kohara K, Arima S, Tamesue N, Shimura H. Toxicities in single chemotherapy with 5-fluorouracil dry syrup and combination chemotherapy with 5-fluorouracil dry syrup and PSK for cancer patients. Jpn J Cancer Chemother. 1979;6:379-85 (in Japanese with English abstract).
103. S Sadahiro T Suzuki Y Maeda A Tanaka A Kamijo C Murayama Y Nakayama T Akiba, et al. 2010 Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma Anticancer Res 30 993 999 20393026 1:CAS:528:DC%2BC3cXlsleksr4%3D
104. Yoshimura A, Asakawa M, Nakai H, Sakai H, Nishiwaki Y, Furuse K, et al. Combined effects of PSK with chemotherapy in the treatment of adenocarcinoma of the lung. Assessment of quality of life (QOL). Biotherapy 1992;6:256-7 (in Japanese with English abstract).
105. Motai H. PSK effectiveness for cancer pain relief: clinical study covering the last 11 years. Biotherapy. 1992;6:950-6 (in Japanese with English abstract).
106. Nomoto K, Matsuo K. Role of immunopotentiators in immunotherapy. Jpn J Cancer Chemother. 1978;5:1135-41 (in Japanese with English abstract).
107. J Sakamoto A Koike S Saji S Teramukai Y Ohashi H Nakazato 1992 Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK Surg Today 22 530 536 1472793 10.1007/BF00308899 1:CAS:528:DyaK3sXht1Wqtb0%3D (Pubitemid 23001054)
108. T Toge Y Yamaguchi 2000 Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count Oncol Rep 75 1157 1161
109. S Tsujitani Y Kakeji H Orita A Watanabe S Kohnoe H Baba, et al. 1992 Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer Anticancer Res 12 645 648 1622120 1:STN:280:DyaK38zitFKmuw%3D%3D
110. Ogoshi K, Tajima T, Mitomi T, Makuuchi, Tsuji K. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother. 1997;45:53-9. (Pubitemid 27444470)
111. R Yoshikawa H Yanagi CH Shen Y Fujiwara M Noda T Yagyu, et al. 2006 ECA39 is a novel distant metastasis-related biomarker in colorectal cancer World J Gastroenterol 12 5884 5889 17007058 1:CAS:528:DC%2BD28Xht1SqsrvP (Pubitemid 44594260)
112. K Yamashita AV Ougolkov H Nakazato K Ito Y Ohashi H Kitakata, et al. 2007 Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic β-catenin activation Dis Colon Rectum 50 1169 1181 17347903 10.1007/s10350-006-0842-5 (Pubitemid 47087457)
113. Y Takahashi M Mai H Nakazato 2005 Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU Anticancer Res 25 1377 1384 15865094 (Pubitemid 40546818)
114. S Ohwada T Ogawa F Makita Y Tanahashi T Ohya N Tomizawa, et al. 2006 Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters Oncol Rep 15 861 868 16525672 1:CAS:528:DC%2BD28Xjs1Kitrg%3D
115. K Sugimachi Y Maehara T Kusumoto T Okamura D Korenaga S Kohnoe, et al. 1995 In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer Anticancer Res 15 2175 2180 8572620 1:CAS:528:DyaK28XhsFWhtbk%3D
116. K Yoshinaga H Saeki K Endo M Morita Y Emi Y Kakeji, et al. 2008 Biomarker research of Krestin (PSK) therapy in gastric and colorectal cancer patients J Jpn Soc Clin Oncol 43 900
117. Sugiyama M, Yoshino I, Kakeji Y, Maehara Y. Gene expression profile in human peripheral blood mononuclear cells upon PSK stimulation. In: Proceedings of the JCA. 2008; p. 452.